🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Metastatic Triple-Negative Breast Cancer

A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer NCT06246968Phase 17 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Pembrolizumab, Cryoablation, Histotripsy A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs NCT06908928Phase 17 sites📍 Duarte📍 La Jolla📍 Aurora Mabwell (Shanghai) Bioscience Co., Ltd. · Tests: bulumtatug fuvedotin, bulumtatug fuvedotin A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer NCT06732323Phase 31 site📍 Beijing Qilu Pharmaceutical Co., Ltd. · Tests: ESG401, Investigator's Choice Chemotherapy Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) NCT07011654Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Sacituzumab govitecan, Naxitamab 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors NCT07189871Phase 1, Phase 25 sites📍 Dothan📍 Grand Rapids📍 Omaha Radiopharm Theranostics, Ltd · Tests: 177Lu-BetaBart, BetaBart + unlabeled BetaBart Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients NCT04159818Phase 21 site📍 Amsterdam The Netherlands Cancer Institute · Tests: Nivolumab, Cisplatin, Low dose doxorubicin Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC NCT05464082Phase 21 site📍 Salt Lake City University of Utah · Tests: Functional Precision Oncology Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer NCT06954480Phase 22 sites📍 London📍 London Queen Mary University of London · Tests: Datopotamab Deruxtecan (Dato-DXd), Durvalumab Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer NCT06635980Phase 21 site📍 Scottsdale Mayo Clinic · Tests: Biopsy of Breast, Biospecimen Collection, Breast Surgery, Chemotherapy, Computed Tomography A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer NCT06508216Phase 1, Phase 21 site📍 Villejuif Gustave Roussy, Cancer Campus, Grand Paris · Tests: Dato-DXd, Durvalumab A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) NCT06926868Phase 2, Phase 3295 sites📍 Hot Springs📍 Cerritos📍 Cerritos Bristol-Myers Squibb · Tests: Iza-bren, Nab-paclitaxel, Paclitaxel, Capecitabine, Carboplatin PRE-ISPY Phase I/II Oncology Platform Program NCT05868226Phase 1, Phase 210 sites📍 Birmingham📍 Phoenix📍 Aurora QuantumLeap Healthcare Collaborative · Tests: ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138 Access to Genetic Testing in Underserved Patients With Cancer NCT06422455NA2 sites📍 Los Angeles📍 Rochester University of Southern California · Tests: Best Practice, Educational Intervention, Electronic Health Record Review, Genetic Counseling, Interview Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer NCT06616987Phase 21 site📍 Seoul Yeon Hee Park · Tests: Sacituzumab Govitecan with pegfilgrastim A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors NCT07229313Phase 17 sites📍 Santa Monica📍 New Have📍 Camperdown Kivu Bioscience Inc. · Tests: KIVU-107 Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers NCT05846789Phase 27 sites📍 Atlanta📍 Carmel📍 Indianapolis Kathy Miller · Tests: SOC Chemotherapy, Tocilizumab/Tocilizumab Biosimilar Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer NCT04947189Phase 1, Phase 21 site📍 Darlinghurst St Vincent's Hospital, Sydney · Tests: Seviteronel-D (Seivteronel in combination with dexamethasone), Docetaxel Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer NCT02926690Phase 18 sites📍 Norwalk📍 Atlanta📍 Honolulu OncoTherapy Science, Inc. · Tests: OTS167PO A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors NCT05706129Phase 1, Phase 210 sites📍 Melbourne📍 Sydney📍 Clermont-Ferrand Lumara Bio Oncologics GmbH · Tests: [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452 Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer NCT06367088Phase 21 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: Cadonilimab A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer NCT06471205Phase 21 site📍 Shanghai Sichuan Baili Pharmaceutical Co., Ltd. · Tests: BL-B01D1, PD-1 Monoclonal Antibody Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642n/a3 sites📍 Phoenix📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Tissue Collection A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer NCT04683679Phase 27 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Pembrolizumab, Olaparib, Radiation A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. NCT06022029Phase 116 sites📍 Los Angeles📍 Tamarac📍 Canton OncoNano Medicine, Inc. · Tests: ONM-501, Cemiplimab Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases NCT07623577Phase 21 site📍 Shanghai Fudan University · Tests: Sacituzumab Tirumotecan (Sac-TMT), bevacizumab A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) NCT04333706Phase 1, Phase 23 sites📍 Los Angeles📍 Los Angeles📍 Gainesville University of Southern California · Tests: Capecitabine, Sarilumab 150mg or 200 mg plus Capecitabine, Sarilumab 150mg plus Capecitabine Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer NCT04722978Phase 31 site📍 Guangzhou Sun Yat-Sen University Cancer Center · Tests: Gemcitabine and carboplatin plus antibiotic (moxifloxacin), Gemcitabine combined with carboplatin plus placebo A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast) NCT07067138NA1 site📍 Bethesda National Cancer Institute (NCI) · Tests: Expression Networks for highLIGHting Tumor vulnerabilities (ENLIGHT), TruSight(R) Oncology 500, TruSeq Matched Tumor No… A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer NCT07078604Phase 21 site📍 Seattle University of Washington · Tests: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Chemotherapy, Computed Tomography, Sargramostim, Biospecimen… A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors NCT07115043Phase 1, Phase 213 sites📍 Grand Rapids📍 St Louis📍 Pittsburgh AstraZeneca · Tests: AZD6750, rilvegostomig
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy